Olympiad Research LP Boosts Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Olympiad Research LP boosted its position in Catalent, Inc. (NYSE:CTLT) by 93.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,009 shares of the company’s stock after purchasing an additional 15,924 shares during the period. Catalent comprises approximately 1.3% of Olympiad Research LP’s portfolio, making the stock its 13th biggest holding. Olympiad Research LP’s holdings in Catalent were worth $1,999,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of CTLT. Mirae Asset Global Investments Co. Ltd. lifted its stake in Catalent by 33.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,789 shares of the company’s stock valued at $1,230,000 after purchasing an additional 5,499 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Catalent by 154.6% during the first quarter. BNP Paribas Financial Markets now owns 216,311 shares of the company’s stock worth $12,211,000 after acquiring an additional 131,360 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Catalent by 10.2% during the first quarter. Nordea Investment Management AB now owns 11,874 shares of the company’s stock worth $672,000 after acquiring an additional 1,096 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Catalent by 8.3% during the first quarter. Daiwa Securities Group Inc. now owns 26,397 shares of the company’s stock worth $1,490,000 after acquiring an additional 2,017 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Catalent during the first quarter worth $625,000.

Catalent Trading Up 2.5 %

Catalent stock opened at $59.95 on Thursday. The stock has a market cap of $10.88 billion, a P/E ratio of -10.92, a PEG ratio of 2.06 and a beta of 1.16. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. Catalent, Inc. has a fifty-two week low of $32.38 and a fifty-two week high of $61.20. The firm’s fifty day moving average price is $60.03 and its 200-day moving average price is $58.03.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The firm’s revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.10) EPS. Equities research analysts forecast that Catalent, Inc. will post 0.95 earnings per share for the current fiscal year.

Insider Activity at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.31% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

CTLT has been the topic of several recent research reports. Robert W. Baird restated a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. StockNews.com downgraded Catalent from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating and eight have given a hold rating to the stock. Based on data from MarketBeat, Catalent has a consensus rating of “Hold” and a consensus target price of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.